UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 19, 2023

 

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

Suite 310 – 815 W. Hastings Street Vancouver, B.C. Canada		V6C 1B4
(Address of Principal Executive Offices)		(Zip Code)

 

(Registrant’s Telephone Number, Including Area Code): (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07: Submission of Matters to a Vote of Security Holders.

 

On December 19, 2023, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:

 

Proposal No. 1—Election of Directors

 

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2024 Annual General Meeting of Shareholders:

 

Nominee		Votes For		% Votes For		Votes Withheld		% Votes Withheld		Broker Non-Votes
Eric A. Adams		160,711		76.09%		50,513		23.91%		1,081,422
Andrew Hull		141,398		66.94%		69,826		33.06%		1,081,422
Janet Grove		141,882		67.17%		69,342		32.83%		1,081,422
Bryan Baldasare		145,659		68.96%		65,565		31.04%		1,081,422
Nicole Lemerond		145,865		69.06%		65,359		30.94%		1,081,422

 

Proposal No. 2—Appointment of Independent Registered Public Accounting Firm

 

The Corporation’s shareholders voted to approve the appointment of Marcum LLP as the independent registered public accounting firm of the Corporation until the 2024 Annual General Meeting of Shareholders or until a successor is named.

 

Votes For		% Votes For		Vote Against		% Votes Against		Abstain		Broker Non- Votes
1,169,259		90.45%		0		0%		123,387		0

 

 

Item 7.01 Regulation FD Disclosure.

 

On December 19, 2023, the Corporation issued a press release announcing the voting results of the meeting. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 99.1.		Press release, dated December 19, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 19, 2023

 

	INMED PHARMACEUTICALS INC.
	By:	/s/ Eric A. Adams
	Name:	Eric A. Adams
	Title:	Chief Executive Officer

 

 

3